{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:10:20Z","timestamp":1779246620043,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","award":["2022R1I1A1A01065244"],"award-info":[{"award-number":["2022R1I1A1A01065244"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","award":["2018R1A5A2025286"],"award-info":[{"award-number":["2018R1A5A2025286"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79428-6","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:55:34Z","timestamp":1732244134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms"],"prefix":"10.1038","volume":"14","author":[{"given":"Han Ah","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-1285","authenticated-orcid":false,"given":"Hwi Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"79428_CR1","doi-asserted-by":"crossref","unstructured":"Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature. Hepatology. (2023).","DOI":"10.1097\/HEP.0000000000000604"},{"key":"79428_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238\u2013250 (2018).","journal-title":"J. Hepatol."},{"key":"79428_CR3","doi-asserted-by":"crossref","unstructured":"Lee, H. H. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. (2023).","DOI":"10.1136\/gutjnl-2023-331003"},{"key":"79428_CR4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/hep.32315","volume":"75","author":"CH Ng","year":"2022","unstructured":"Ng, C. H. et al. Placebo effect on progression and regression in NASH: evidence from a meta-analysis. Hepatology. 75, 1647\u20131661 (2022).","journal-title":"Hepatology"},{"key":"79428_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","volume":"17","author":"MAT Han","year":"2019","unstructured":"Han, M. A. T. et al. Rates of and factors Associated with Placebo response in trials of Pharmacotherapies for nonalcoholic steatohepatitis: systematic review and Meta-analysis. Clin. Gastroenterol. Hepatol. 17, 616\u2013629e626 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"79428_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3350\/cmh.2022.0095","volume":"29","author":"T Nakatsuka","year":"2023","unstructured":"Nakatsuka, T. & Tateishi, R. Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin. Mol. Hepatol. 29, 51\u201364 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"79428_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal, F. et al. Effect of metabolic traits on the risk of cirrhosis and Hepatocellular Cancer in nonalcoholic fatty liver disease. Hepatology. 71, 808\u2013819 (2020).","journal-title":"Hepatology"},{"key":"79428_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst. Rev. 10, 89 (2021).","journal-title":"Syst. Rev."},{"key":"79428_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"79428_CR10","doi-asserted-by":"crossref","unstructured":"Higgins, J. P., Li, T. & Deeks, J. J. Choosing effect measures and computing estimates of effect. Cochrane Handb. Syst. Reviews Interventions 2019:143\u2013176 .","DOI":"10.1002\/9781119536604.ch6"},{"key":"79428_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials. 7, 177\u2013188 (1986).","journal-title":"Control Clin. Trials"},{"key":"79428_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","volume":"334","author":"J Fletcher","year":"2007","unstructured":"Fletcher, J. What is heterogeneity and is it. Important? Bmj. 334, 94\u201396 (2007).","journal-title":"Important? Bmj"},{"key":"79428_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout, J., Ioannidis, J. P. & Borm, G. F. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med. Res. Methodol. 14, 25 (2014).","journal-title":"BMC Med. Res. Methodol."},{"issue":"25","key":"79428_CR14","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1002\/sim.7411","volume":"36","author":"D Jackson","year":"2017","unstructured":"Jackson, D. et al. The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns? Stat. Med. 36 (25), 3923\u20133934 (2017).","journal-title":"Stat. Med."},{"key":"79428_CR15","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"79428_CR16","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl. J. Med. 362, 1675\u20131685 (2010).","journal-title":"N Engl. J. Med."},{"key":"79428_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1756283X09105462","volume":"2","author":"WW Shields","year":"2009","unstructured":"Shields, W. W., Thompson, K. E., Grice, G. A., Harrison, S. A. & Coyle, W. J. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Th. Adv. Gastroenterol. 2, 157\u2013163 (2009).","journal-title":"Th. Adv. Gastroenterol."},{"key":"79428_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor, K. D. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 39, 770\u2013778 (2004).","journal-title":"Hepatology"},{"key":"79428_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","volume":"23","author":"TR Joy","year":"2017","unstructured":"Joy, T. R. et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J. Gastroenterol. 23, 141\u2013150 (2017).","journal-title":"World J. Gastroenterol."},{"key":"79428_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes Mellitus: a Randomized Trial. Ann. Intern. Med. 165, 305\u2013315 (2016).","journal-title":"Ann. Intern. Med."},{"key":"79428_CR21","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","volume":"12","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat. Commun. 12, 5503 (2021).","journal-title":"Nat. Commun."},{"key":"79428_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc19-0167","volume":"42","author":"F Bril","year":"2019","unstructured":"Bril, F. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a Randomized Controlled Trial. Diabetes Care. 42, 1481\u20131488 (2019).","journal-title":"Diabetes Care"},{"key":"79428_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","volume":"49","author":"S Dasarathy","year":"2015","unstructured":"Dasarathy, S. et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 49, 137\u2013144 (2015).","journal-title":"J. Clin. Gastroenterol."},{"key":"79428_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl. J. Med. 355, 2297\u20132307 (2006).","journal-title":"N Engl. J. Med."},{"key":"79428_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi, K. et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes. Metab. 21, 812\u2013821 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"79428_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","volume":"19","author":"A Uygun","year":"2004","unstructured":"Uygun, A. et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 19, 537\u2013544 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"79428_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson, J. W. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 61, 1923\u20131934 (2018).","journal-title":"Diabetologia"},{"key":"79428_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12916-016-0638-y","volume":"14","author":"I Barchetta","year":"2016","unstructured":"Barchetta, I. et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 14, 92 (2016).","journal-title":"BMC Med."},{"key":"79428_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl, S. et al. Empagliflozin effectively lowers Liver Fat Content in Well-controlled type 2 diabetes: a Randomized, Double-Blind, phase 4, placebo-controlled trial. Diabetes Care. 43, 298\u2013305 (2020).","journal-title":"Diabetes Care"},{"key":"79428_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/dom.12680","volume":"18","author":"A Dutour","year":"2016","unstructured":"Dutour, A. et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes. Metab. 18, 882\u2013891 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"79428_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"B Gaborit","year":"2021","unstructured":"Gaborit, B. et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc. Diabetol. 20, 57 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"79428_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","volume":"63","author":"MB Bizino","year":"2020","unstructured":"Bizino, M. B. et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 63, 65\u201374 (2020).","journal-title":"Diabetologia"},{"key":"79428_CR33","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","volume":"59","author":"MM Smits","year":"2016","unstructured":"Smits, M. M. et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia. 59, 2588\u20132593 (2016).","journal-title":"Diabetologia"},{"key":"79428_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen, N. et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes. Metab. 21, 84\u201394 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"79428_CR35","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/dom.13268","volume":"20","author":"K Kantartzis","year":"2018","unstructured":"Kantartzis, K. et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes. Metab. 20, 1793\u20131797 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"79428_CR36","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1007\/s00125-019-4956-4","volume":"62","author":"MJ Skytte","year":"2019","unstructured":"Skytte, M. J. et al. A carbohydrate-reduced high-protein diet improves HbA(1c) and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia. 62, 2066\u20132078 (2019).","journal-title":"Diabetologia"},{"key":"79428_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00125-021-05628-8","volume":"65","author":"MN Thomsen","year":"2022","unstructured":"Thomsen, M. N. et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia. 65, 506\u2013517 (2022).","journal-title":"Diabetologia"},{"key":"79428_CR38","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.2337\/dc10-0856","volume":"33","author":"M Lazo","year":"2010","unstructured":"Lazo, M. et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 33, 2156\u20132163 (2010).","journal-title":"Diabetes Care"},{"key":"79428_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jceh.2014.03.041","volume":"4","author":"KT Shenoy","year":"2014","unstructured":"Shenoy, K. T. et al. Metadoxine Versus Placebo for the treatment of non-alcoholic steatohepatitis: a Randomized Controlled Trial. J. Clin. Exp. Hepatol. 4, 94\u2013100 (2014).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"79428_CR40","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","volume":"21","author":"YH Li","year":"2015","unstructured":"Li, Y. H. et al. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J. Gastroenterol. 21, 7008\u20137013 (2015).","journal-title":"World J. Gastroenterol."},{"key":"79428_CR41","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay, M. S. et al. Effect of Empagliflozin on Liver Fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 41, 1801\u20131808 (2018).","journal-title":"Diabetes Care"},{"key":"79428_CR42","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay, M. S. et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 63, 2434\u20132445 (2020).","journal-title":"Diabetologia"},{"key":"79428_CR43","doi-asserted-by":"publisher","first-page":"109781","DOI":"10.1016\/j.diabres.2022.109781","volume":"186","author":"K Horibe","year":"2022","unstructured":"Horibe, K. et al. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial. Diabetes Res. Clin. Pract. 186, 109781 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"79428_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","volume":"35","author":"MA Nogueira","year":"2016","unstructured":"Nogueira, M. A. et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Clin. Nutr. 35, 578\u2013586 (2016).","journal-title":"Clin. Nutr."},{"key":"79428_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","volume":"5","author":"R Loomba","year":"2020","unstructured":"Loomba, R. et al. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 829\u2013838 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79428_CR46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku, A. et al. The SGLT2 inhibitor Dapagliflozin reduces Liver Fat but does not affect tissue insulin sensitivity: a Randomized, Double-Blind, placebo-controlled study with 8-Week treatment in type 2 diabetes patients. Diabetes Care. 42, 931\u2013937 (2019).","journal-title":"Diabetes Care"},{"key":"79428_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12876-022-02550-0","volume":"22","author":"KA Seeberg","year":"2022","unstructured":"Seeberg, K. A. et al. Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study. BMC Gastroenterol. 22, 448 (2022).","journal-title":"BMC Gastroenterol."},{"key":"79428_CR48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3350\/cmh.2021.0383","volume":"28","author":"HS Shin","year":"2022","unstructured":"Shin, H. S., Jun, B. G. & Yi, S. W. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases. Clin. Mol. Hepatol. 28, 773\u2013789 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"79428_CR49","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera, L. et al. High prevalence of NASH and Advanced Fibrosis in Type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care. 46, 1354\u20131362 (2023).","journal-title":"Diabetes Care"},{"key":"79428_CR50","doi-asserted-by":"publisher","first-page":"h4672","DOI":"10.1136\/bmj.h4672","volume":"351","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick, P. & Greenwood, N. Understanding the Hawthorne effect. Bmj. 351, h4672 (2015).","journal-title":"Bmj"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79428-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:04:16Z","timestamp":1732518256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79428"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79428-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3847827\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was supported in part by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (grant numbers 2018R1A5A2025286 and 2022R1I1A1A01065244). The sponsors had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The funding source was not involved in the design or implementation of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"This study was registered with PROSPERO (registration number: CRD42023455528).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration number"}}],"article-number":"28951"}}